Pasvolsky, O., Afrough, A., Feng, L., Dong, W., Richards, T., Davis, J. A., … Khouri, J. (2024). Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab. In Blood (Vol. 144, pp. 3337–3337). American Society of Hematology. https://doi.org/10.1182/blood-2024-206357

Pasvolsky, Oren, Aimaz Afrough, Lei Feng, Wenli Dong, Tiffany Richards, James A. Davis, Danai Dima, et al. “Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab.” In Blood, 144:3337–3337. American Society of Hematology, 2024. https://doi.org/10.1182/blood-2024-206357.

Pasvolsky O, Afrough A, Feng L, Dong W, Richards T, Davis JA, et al. Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab. In: Blood. American Society of Hematology; 2024. p. 3337–3337.

Pasvolsky, Oren, et al. “Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab.” Blood, vol. 144, no. Supplement 1, American Society of Hematology, 2024, pp. 3337–3337. Crossref, doi:10.1182/blood-2024-206357.

Pasvolsky O, Afrough A, Feng L, Dong W, Richards T, Davis JA, Dima D, Grajales-Cruz A, Vazquez-Martinez MA, Sannareddy A, Goel U, Banerjee R, Gaballa MR, Lieberman-Cribbin A, Rana MS, Julian K, Ferreri CJ, Shune LO, DeJarnette S, Ouchveridze E, Susanibar-Adaniya S, Portuguese AJ, Forsberg PA, Hosoya H, Mikkilineni L, Kaur G, Rossi A, Herr MM, Eberwein E, Lin C, Blue B, Raza S, Lin Y, McGuirk JP, Atrash S, Sborov DW, Voorhees PM, Anwer F, Hansen DK, Patel KK, Sidana S, Cowan AJ, Anderson LD, Richard S, Garfall AL, Lee HC, Khouri J. Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab. Blood. American Society of Hematology; 2024. p. 3337–3337.